These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 2659861)

  • 21. Differential alteration of striatal D-1 and D-2 receptors induced by the long-term administration of haloperidol, sulpiride or clozapine to rats.
    Jenner P; Rupniak NM; Marsden CD
    Psychopharmacology Suppl; 1985; 2():174-81. PubMed ID: 3159009
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modulation of acetylcholine release by D1, D2 dopamine receptors in rat striatum under freely moving conditions.
    Ajima A; Yamaguchi T; Kato T
    Brain Res; 1990 Jun; 518(1-2):193-8. PubMed ID: 1975213
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of long-term L-dopa administration on the dopaminergic and cholinergic (muscarinic) receptors of striatum in 6-hydroxydopamine lesioned rats.
    Suga M
    Life Sci; 1980 Sep; 27(10):877-82. PubMed ID: 7412476
    [No Abstract]   [Full Text] [Related]  

  • 24. N-methyl-D-aspartate-evoked release of [3H]acetylcholine in striatal compartments of the rat: regulatory roles of dopamine and GABA.
    Blanchet F; Kemel ML; Gauchy C; Desban M; Perez S; Glowinski J
    Neuroscience; 1997 Nov; 81(1):113-27. PubMed ID: 9300405
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine. I. Effects of intranigral or intracerebroventricular 6-hydroxydopamine lesions of the mesostriatal dopamine system.
    Joyce JN
    Exp Neurol; 1991 Sep; 113(3):261-76. PubMed ID: 1833219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Repeated administration of HA-966 and haloperidol to rats: similar tolerance to striatal dopamine accumulation after HA-966 challenge, but dissimilar effects on striatal [3H]spiperone binding.
    Van der Krogt JA; Van Valkenburg CF; Belfroid RD; Heerkens CB
    Eur J Pharmacol; 1988 Dec; 158(1-2):29-35. PubMed ID: 3220118
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SCH23390 effects on apomorphine-induced responses of nigral dopaminergic neurons.
    Napier TC; Givens BS; Schulz DW; Bunney BS; Breese GR; Mailman RB
    J Pharmacol Exp Ther; 1986 Mar; 236(3):838-45. PubMed ID: 3512819
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Age-related decrements in the muscarinic enhancement of K+-evoked release of endogenous striatal dopamine: an indicator of altered cholinergic-dopaminergic reciprocal inhibitory control in senescence.
    Joseph JA; Dalton TK; Hunt WA
    Brain Res; 1988 Jun; 454(1-2):140-8. PubMed ID: 2900662
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SCH 23390 may alter dopamine-mediated motor behaviour via striatal D-1 receptors.
    Boyce S; Kelly E; Davis A; Fleminger S; Jenner P; Marsden CD
    Biochem Pharmacol; 1985 May; 34(10):1665-9. PubMed ID: 2988552
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Decreased striatal release of acetylcholine following withdrawal from long-term treatment with haloperidol: modulation by cholinergic, dopamine-D1 and -D2 mechanisms.
    Friedman E; Wang HY; Butkerait P
    Neuropharmacology; 1990 Jun; 29(6):537-44. PubMed ID: 2200974
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dopamine denervation does not alter in vivo 3H-spiperone binding in rat striatum: implications for external imaging of dopamine receptors in Parkinson's disease.
    Bennett JP; Wooten GF
    Ann Neurol; 1986 Apr; 19(4):378-83. PubMed ID: 3707090
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Similar pharmacological properties of 8-OH-DPAT and alnespirone (S 20499) at dopamine receptors: comparison with buspirone.
    Protais P; Lesourd M; Comoy E
    Eur J Pharmacol; 1998 Jul; 352(2-3):179-87. PubMed ID: 9716353
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ACTH/MSH-like peptides inhibit the binding of dopaminergic ligands to the dopamine D2 receptor in vitro.
    Florijn WJ; De Boer T; Tonnaer JA; Van Nispen JW; Versteeg DH
    Eur J Pharmacol; 1991 May; 207(1):43-50. PubMed ID: 1680721
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alterations in muscarinic control of striatal dopamine autoreceptors in senescence: a deficit at the ligand-muscarinic receptor interface?
    Joseph JA; Dalton TK; Roth GS; Hunt WA
    Brain Res; 1988 Jun; 454(1-2):149-55. PubMed ID: 3136856
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential alterations in striatal dopamine receptor sensitivity induced by repeated administration of clinically equivalent doses of haloperidol, sulpiride or clozapine in rats.
    Rupniak NM; Kilpatrick G; Hall MD; Jenner P; Marsden CD
    Psychopharmacology (Berl); 1984; 84(4):512-9. PubMed ID: 6441952
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Autoradiographic identification of D1 dopamine receptors labelled with [3H]dopamine: distribution, regulation and relationship to coupling.
    Hervé D; Trovero F; Blanc G; Glowinski J; Tassin JP
    Neuroscience; 1992; 46(3):687-700. PubMed ID: 1532052
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modulation by estradiol and progesterone of the GTP effect on striatal D-2 dopamine receptors.
    Lévesque D; Di Paolo T
    Biochem Pharmacol; 1993 Feb; 45(3):723-33. PubMed ID: 8095140
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of dopamine autoreceptor and [3H]spiperone binding sites in vitro with classical and novel dopamine receptor agonists.
    Lehmann J; Briley M; Langer SZ
    Eur J Pharmacol; 1983 Mar; 88(1):11-26. PubMed ID: 6133762
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of direct competition for, and indirect influences on, striatal muscarinic cholinergic receptors: in vivo [3H]quinuclidinyl benzilate binding in rats.
    Pelham RW; Munsat TL
    Brain Res; 1979 Aug; 171(3):473-80. PubMed ID: 476482
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dopamine receptor changes in response to prolonged treatment with L-dopa.
    Groppetti A; Flauto C; Parati E; Vescovi A; Rusconi L; Parenti M
    J Neural Transm Suppl; 1986; 22():33-45. PubMed ID: 2946813
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.